Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-06 | NCT03625037 | |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-06 | NCT05948475 | |
| Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Active, not recruiting | Not applicable | 2026-01-15 | NCT01599559 | |
| Phase III Radium 223 mCRPC-PEACE III | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2025-09-19 | NCT02194842 | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-09-08 | NCT05063786 | |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, astrocytoma (excluding glioblastoma), benign urinary system neoplasm, brain disorder, central nervous system cancer, central nervous system disorder, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, glioblastoma, glioma, intestinal disorder, kidney cancer, kidney disorder, lung cancer, lung disorder, lung neoplasm, malignant colon neoplasm, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, nervous system disorder, neuroepithelial neoplasm, non-small cell lung carcinoma, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, stomach disorder, thyroid gland disorder, thyroid tumor, urinary system disorder | Recruiting | Phase 2 | 2025-06-27 | NCT03175224 | |
| A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2024-11-12 | NCT01957436 | |
| Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 1 / Phase 2 | 2022-08-04 | NCT04502394 |